Future directions in therapy for chronic hepatitis C
Open Access
- 1 January 2008
- journal article
- review article
- Published by SAGE Publications in Antiviral Therapy
- Vol. 13 (1_suppl) , 31-36
Abstract
The development of new antiviral therapies in the treatment of hepatitis C virus (HCV) is reviewed, including a discussion of the potential advances that this treatment will bring. Data from new molecules in Phase I and II clinical trials, specifically polymerase and protease inhibitors, will be discussed. The potential for resistance has been reported when these have been used as monotherapy. However, their use in combination with pegylated interferon, particularly in the presence of ribavirin, has resulted in significant improvements in antiviral activity. Preliminary studies have confirmed that the new molecules are well tolerated and further clinical studies are underway to evaluate their efficacy. Nevertheless, because of its critical role at all stages of therapy, pegylated interferon is likely to remain the cornerstone of HCV therapy.Keywords
This publication has 16 references indexed in Scilit:
- Telaprevir and pegylated interferon–alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patientsHepatology, 2007
- Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor TelaprevirGastroenterology, 2007
- The Hepatitis C Virus Life Cycle as a Target for New Antiviral TherapiesGastroenterology, 2007
- [14] CLEARANCE OF HCVRNA WITH VALOPICITABINE (NM) PLUS PEG-INTERFERON IN TREATMENT-NAIVE PATIENTS WITH HCV-1 INFECTION: RESULTS AT 24 AND 48 WEEKSJournal of Hepatology, 2007
- SCH 503034, a Novel Hepatitis C Virus Protease Inhibitor, Plus Pegylated Interferon α-2b for Genotype 1 NonrespondersGastroenterology, 2007
- 10 Directed evolution of novel gene shuffled interferon alphas for the treatment of hepatitis CJournal of Hepatology, 2006
- American Gastroenterological Association Medical Position Statement on the Management of Hepatitis CGastroenterology, 2006
- In Vitro Studies of Cross-resistance Mutations against Two Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061Journal of Biological Chemistry, 2005
- ReplyJournal of Hepatology, 2005
- In Vitro Resistance Studies of Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061Journal of Biological Chemistry, 2004